Sanofi has announced its intention to invest at least $20 billion in the US through 2030.  Although not detailing specifics, the company says that “the expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to US manufacturing.” 

The company says it plans to expand its US manufacturing capacity, both through direct investments in Sanofi sites, as well as through partnerships with other domestic manufacturers. 

“Sanofi’s 13,000 US-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas,” said Sanofi CEO Paul Hudson, in a May 14, 2025, press statement. “Our expected investments in the US will be substantial and will help ensure the production of key medicines in the US.” 

In its pharmaceuticals business, Sanofi has three R&D sites in the US (as of December 31, 2024): (1) Bridgewater, New Jersey; (2) Cambridge, Massachusetts; and (3) Framingham/Waltham, Massachusetts. Outside the US, it has two operational sites in France: Montpellier and Vitry-sur-Seine/Alfortville; two sites in the rest of Europe (Germany and Belgium), the larger of which is in Frankfurt, Germany; and three sites in China (Beijing, Shanghai and Chengdu). 

In its vaccines business, it has three US R&D sites (as of December 31, 2024): (1) Swiftwater, Pennsylvania; (2) Cambridge, Massachusetts; and (3) Orlando, Florida. Outside the US, it has vaccine R&D sites in Marcy-L’Etoile/Lyon, France and Toronto, Canada. 

In terms of manufacturing, its medicines industrial operations are organized through end-to-end clusters with four dedicated biotechnology hubs: Paris/Lyon (France), Frankfurt (Germany), Geel (Belgium) and the Boston area (US), as of December 31, 2024. In May 2024, Sanofi announced plans for a major investment to increase the production capabilities of its facility at Vitry-sur-Seine, France. It also has end-to-end clusters with chemistry, pharmaceutical and injectable sites organized through a network of regional and local industrial sites. A dedicated Launch Sites cluster was implemented, from active pharmaceutical ingredient (API) manufacturing to finished goods packaging (in Sisteron, Aramon, Ambarès, France and Scoppito, Italy). Its Frankfurt facility is its principal site for the manufacture of diabetes treatments. Also in 2024, the company announced major investments in the production of insulin APIs at new facilities in Frankfurt (Germany) and Beijing (China). 

For the industrial operations in its vaccines business, major investments were announced in 2020 and 2021 with a new facility in France (Neuville-Sur-Saone) and a new facility in Singapore for its vaccine pipeline, as reported by the company in its 2024 annual financial filing. Other major investments were underway in France (including construction of a new influenza vaccine building at Val-de-Reuil), in Canada (a new pertussis vaccine building) as well as investments in the US, and Mexico. 

Source: Sanofi